SlideShare ist ein Scribd-Unternehmen logo
1 von 35
1
Hypertensive disorders of
pregnancy
Prof. Adel Abul-Heija
2
Introduction
1. Hypertensive disorders of pregnancy are
one of the leading causes of maternal
mortality.
2. Worldwide: 50,000 women die each year.
3. Jordan: 4th. Cause of maternal death after
(hemorrhage, thrombo-embolism, and
sepsis. (Jordan MMR 19.1 per 100000 live
birth, 2007-2008)
3
Diagnosis of hypertension in
pregnancy
 A systolic BP of > 140 mmHg, a diastolic BP
of > 90 mmHg, or both.
 Hypertension is considered severe when BP >
160 for systolic or > 110 for diastolic.
 It required at lest two determinations with at
least 6 hours apart of bed rest.
4
How to measure BP in pregnant
woman
 Women should be allowed to sit quietly for 10-20 minutes before
each blood pressure measurement.
 Blood pressure should be measured in the sitting position, with the
cuff at the level of the heart.
 Korotkoff sounds I (the first sound) and V (the disappearance of
sound) should be used to denote the systolic blood pressure
(SBP) and DBP, respectively.
 In about 5% of women, an exaggerated gap exists between the
fourth (muffling) and fifth (disappearance) Korotkoff sounds, with
the fifth sound approaching zero. In this setting, both the fourth
and fifth sounds should be recorded (eg, 120/80/40, with sound I =
120, sound IV = 80, and sound V = 40), because the fourth sound
will more closely approximate the true DBP.
5
Diagnosis of Protienurea in
pregnancy
 Proteinuria:
 ≥ 300mg/24 hours urine.
 ≥ +1 dipstick. (only applicable if the others are not
avialables)
 Urinary Protein:creatinine ratio:
 At least 0.3 (each measured as mg/dl)
6
Classifications
 Gestational hypertension.
 Preeclampsia-Eclampsia.
 Chronic hypertension with pregnancy.
 Chronic hypertension with
Superimposed preeclampsia.
7
Definitions
 Gestational hypertension:
– Hypertension for first time after 20 w, without
Proteinuria. BP returns to normal before 12
weeks postpartum.
 Chronic hypertension with pregnancy:
– Hypertension antedates pregnancy and detected
before 20 w, & lasts more than 12 weeks
postpartum.
8
Definitions
– Preeclampsia:
 The development of hypertension and Proteinuria after
20 weeks.
 May occur earlier in vesicular mole or multiple
pregnancy.
 Preeclampsia is diagnosed also in the presence of
sever features even in the absence of protienurea (see
next slide).
– Eclampsia:
 The occurrence of tonic-clonic convulsions (without
any neurological disease) in a woman with pre-
eclampsia.
9
Definitions
 Superimposed pre-eclampsia:
¤ It is the new development of Proteinuria
after 20 weeks gestation in a patient with
chronic hypertension
10
11
Incidence of hypertensive disorders in
pregnancy
 Gestational hypertension occurs in around 5-6% of all
pregnancies. More common in primigravida. Most cases are
diagnosed after 34 weeks.
 PE complicates 1-2% of all pregnancies. 4-7% of first
pregnancies (1 in 4 of PIH) and 1% of subsequent
pregnancies, rising to 16% with history of preeclampsia in
first pregnancy.
 Around 5-10% of PE cases are severe.
 Approximately 1% of pregnancies are complicated by
chronic hypertension and 20-25% of women with chronic
hypertension develop preeclampsia during pregnancy.
12
Pre-eclampsia (PE):
Definition:
A diastolic BP > 90 mmHg, on at least two
occasions after 20 weeks of gestation
accompanied by significant proteinuria (>
300 mg/24h) and/or other systemic severe
manifestations mentioned before.
13
Aetiology of PE:
PE is the disease of theories:
1. Damage to the vascular endothelial cells.
2. Abnormal lipid metabolism.
3. Reduced anti-oxidant status.
4. Altered catecholamine homeostasis.
5. Abnormal dietary calcium, magnesium, or selenium.
6. Reduced production of nitric oxide.
7. Abnormal immune response to pregnancy.
14
Patho-physiology of PE:
 Abnormal placentation is central to the pathogenesis
of PE.
 In PE there is reduction in the synthesis of nitric
oxide and prostacyclin and increased production of
endothelin and sensitivity to angiotensin. This result
in to vasospasm and endothelial dysfunction, with
subsequent platelet activation and micro thrombus
formation. These are responsible for features of PE.
15
Multi-system Features Of
Preeclampsia
Multi-organ disease
Kidney
Systemic blood vessels
Liver
Fetus
Cerebral blood vessels
HELLP syndrome
IUGR
Eclampsia
Proteinuria
Hypertension
16
Clinical features of PE:
Maternal syndrome:
1. PIH.
2. Proteinuria.
3. Generalized oedema.
4. Hyperuricaemia.
5. Increased haematocrit.
6. Thrombocytopenia & DIC.
7. Reduced antithrombin III.
8. Abnormal liver function tests.
9. Hypocalciuria.
10. Seizures, cortical blindness,
retinal detachment (eclampsia).
Fetal syndrome:
1. IUGR.
2. Fetal hypoxaemia.
17
Prevention of PE:
 Aspirin: Low dose (81mg/day) increases the
prostacycline to thromboxan ratio and prevent platelets
aggregation. It should be used from 12 weeks of
pregnancy in women at risk.
 Calcium supplementation ( may reduce severity in
women with low intake of calcium.
 Antioxidant: vit.C or vit.E (not effective)
 Restriction of dietary salt (not effective)
18
High risk women that need aspirin
 Maternal disorders:
– Chronic hypertension
– Renal diseases
– Diabetes
– Autoimmune conditions
 First pregnancy
 Multiple pregnancy
 Maternal BMI > 25
 H/O preeclampsia
 Age > 40 years
19
Investigations for PE:
 Urinalysis.
 24 h urine collection for total protein.
 Renal function (urea,uric acid,s. creatinine).
 Full blood count (platelets and haematocrit).
 Liver function tests.
 Coagulation profile if delivery is indicated.
 Fetal biophysical profile and Doppler study.
20
Management of PE:
 Diagnosis of PE requires admission for bed
rest and close monitoring for mother and fetus.
 If the diastolic BP is 90-95mmHg with only 1+
protein in the urine, out-patient management
could be followed.
 The definitive treatment for PE is delivery. But
this depend on gestational age and feto-
maternal well-being.
21
Management of PE (cont.):
Antihypertensive therapy:
 Treating the hypertension is mainly to reduce the maternal
complications. It will not improve fetal condition.
Acute treatment of severe hypertension:
 Hydralazine: 5mg IV repeated every 20-30 min.
 Nifedipine: 10mg orally repeated at 30 min. IV infusion can be
used in severe cases.
 Labetalol:10-20mg IV .
 The dose can be doubled every 10 minutes if proper
response is not achieved.
 Magnesium Sulphate should be given in the management of
all cases of severe preeclampsia to prevent eclampsia.
22
Indications for delivery in PE:
 Term pregnancy.
 Severe uncontrolled hypertension (>160/110).
 Haemolysis with thrombocytopenia.
 Progressive symptoms (headache, visual disturbances,
epigastric pain).
 Pulmonary oedema.
 Renal failure with oliguria.
 Eclampsia.
 Fetal compromise ( abnormal biophysical profile).
23
Management of labour and
delivery:
 The mode of delivery is determined by Bishop’s score
and feto-maternal well-being.
 Induction of labour is commonly used, but CS is
needed in large number of cases.
 Fluids input and output should be monitored.
 Prolonged pushing by the mother should be avoided.
 Ergometrine should be avoided.
 Pain relief is optimal (epidural analgesia if no signs of
DIC).
24
Complications of severe PE:
Eclampsia: Occurrence of convulsions in association with
PE.
 Incidence: 5 in 10 000 deliveries and 1-2% of severe
PE cases.
 High maternal and fetal mortality.
 It can occur ante-natally, intra-partum and post-partum.
 The patho-physiology is cerebral vasospasm leading to
ischemia and cerebral edema.
25
Eclampsia:
Diagnosis:
 Women manifest excitability or hyperflexia prior
to onset of seizure.
 Tonic-clonic convulsions with small period of
coma.
 Prolonged coma mains CVA.
26
Management of eclampsia:
 During seizure: Maintain airway, Administer oxygen
and avoid supine hypotension.
 Anticonvulsant therapy:
1. Magnesium sulphate 4-6 g IV followed by a
maintenance infusion of 1-2 g / h.
2. Diazepam 20mg IV followed by a maintenance
infusion as required.
3. Phynenton
 Anticonvulsant should be continued for at least 24 h
after the last convulsion.
 CS is indicated unless the mother is in active labour.
27
Magnesium Sulfate (MgSO4):
 It can be given IV or IM or SC
– The therapeutic level is 4-7mEq/L.
– The total dose of MgSO4 should not exceed 24 gms in 24
hours .
 The dose of MgSO4 is monitored by:
 Preserved patellar reflex. (7-10 mEq/L)
 Respiratory rate >16/min. (10-13 mEq/L)
 Urine output >100ml/4hours. (15-25 mEq/L)
 Serum Mg++ level.
 Is stopped 24 hours after delivery.
 Antidote is ca gluconate
28
Complications of severe PE:
HELLP syndrome: Occurs in the absence of hypertension.
H: haemolysis.
EL: elevated liver enzymes.
LP: low platelet count.
 Present with epigastric pain, tender liver, nausea & vomiting.
 Headache and arterial hypertension.
 Carries high maternal (acute renal failure & pulmonary odema)
and fetal mortality.
 Treatment similar to eclampia & DIC. Platelet transfusion and
cortico-steroids are necessary.
 Delivery is the treatment of choice.
29
Chronic hypertension in pregnancy
Causes of CHT:
1. Essential hypertension.
2. Renal diseases (glomerulonephritis, polycystic
disease, diabetic nephropathy, renal artery stenosis).
3. Collagen vascular diseases ( systemic lupus
erythematosus, scleroderma).
4. Coarctation of the aorta.
5. Phaeochromocytoma.
30
Chronic hypertension in pregnancy
 The main concern that one third of these women will
develop superimposed PIH.
Risk factors for preeclampsia in CHT:
1. Renal disease.
2. Maternal age > 40 years.
3. Diabetes.
4. SLE.
5. Coarctation of the aorta.
6. BP > 160/100 mmHg in early pregnancy.
31
Chronic hypertension in pregnancy
Feto-Maternal risks:
1. Eclampsia.
2. Abruptio-placenta.
3. Heart failure.
4. Intracerebral haemorrhage.
5. IUGR.
32
Long-term treatment of hypertension
This is used mainly in CHD.
 Methyldopa is the most common in use (least
side effects). 1-2 g / day in three divided doses.
 Nifedipine 40 mg / day in two divided doses.
 Labetolol and Hydralazine can also be used.
 ACE inhibitors, Angiotensin II blocker, and
Chlorothiazide should be avoided because of
teratogenic effect.
33
Chronic hypertension in pregnancy
Management:
 Investigations should be performed to diagnose the
cause of hypertension.
 If the woman is on antihypertensive drugs, she should
continue on it, except for angiotensin converting
enzyme inhibitors (captoprel) because of risk of fetal
damage. Care should be taken not to excessively
lower the BP as this may affect the fetal healthy.
 Maternal and fetal well-being should be monitored
through the pregnancy.
34
Chronic hypertension in pregnancy
Management (cont.):
 In severe cases admission is needed.
 The obstetric management is similar to that of
preeclampsia.
 Timing the delivery must be individualized
according to the feto-maternal well-being.
 Induction of labour or CS should be selected
according to the case.
35

Weitere ähnliche Inhalte

Was ist angesagt?

Vomiting of pregnancy and hyperemesis gravidarum. Prof Aboubakr Elnashar
Vomiting of pregnancy and hyperemesis gravidarum. Prof Aboubakr ElnasharVomiting of pregnancy and hyperemesis gravidarum. Prof Aboubakr Elnashar
Vomiting of pregnancy and hyperemesis gravidarum. Prof Aboubakr Elnashar
Aboubakr Elnashar
 
Ectopic pregnancy
Ectopic pregnancyEctopic pregnancy
Ectopic pregnancy
drmcbansal
 
Intrauterine growth restriction
Intrauterine growth restrictionIntrauterine growth restriction
Intrauterine growth restriction
Farrukh Masood
 
Intra uterine growth retardation
Intra uterine growth retardationIntra uterine growth retardation
Intra uterine growth retardation
dhpatel_2005
 

Was ist angesagt? (20)

Hyperemesis gravidarum
Hyperemesis gravidarumHyperemesis gravidarum
Hyperemesis gravidarum
 
Eclampsia preeclampsia
Eclampsia preeclampsia Eclampsia preeclampsia
Eclampsia preeclampsia
 
Vomiting of pregnancy and hyperemesis gravidarum. Prof Aboubakr Elnashar
Vomiting of pregnancy and hyperemesis gravidarum. Prof Aboubakr ElnasharVomiting of pregnancy and hyperemesis gravidarum. Prof Aboubakr Elnashar
Vomiting of pregnancy and hyperemesis gravidarum. Prof Aboubakr Elnashar
 
Vbac
VbacVbac
Vbac
 
Step wise pelvic devascularisation
Step wise pelvic devascularisationStep wise pelvic devascularisation
Step wise pelvic devascularisation
 
Ectopic pregnancy
Ectopic pregnancyEctopic pregnancy
Ectopic pregnancy
 
Pregnancy and Liver Diseases
Pregnancy and Liver DiseasesPregnancy and Liver Diseases
Pregnancy and Liver Diseases
 
Malpresentation (face, brow)
Malpresentation (face, brow)Malpresentation (face, brow)
Malpresentation (face, brow)
 
Ecv rcog2006
Ecv rcog2006Ecv rcog2006
Ecv rcog2006
 
Thyroid diseases in pregnancy PPT
Thyroid diseases in pregnancy PPTThyroid diseases in pregnancy PPT
Thyroid diseases in pregnancy PPT
 
Intrauterine growth restriction
Intrauterine growth restrictionIntrauterine growth restriction
Intrauterine growth restriction
 
Management of hypertensive disorders in pregnancy
Management of hypertensive disorders in pregnancyManagement of hypertensive disorders in pregnancy
Management of hypertensive disorders in pregnancy
 
pregnancy dating, assessment gesational age
pregnancy dating, assessment gesational agepregnancy dating, assessment gesational age
pregnancy dating, assessment gesational age
 
Hypertension in pregnancy
Hypertension in pregnancyHypertension in pregnancy
Hypertension in pregnancy
 
Abnormal labour
Abnormal labourAbnormal labour
Abnormal labour
 
Itp in pregnancy
Itp in pregnancyItp in pregnancy
Itp in pregnancy
 
Cholestasis of pregnancy
Cholestasis of pregnancyCholestasis of pregnancy
Cholestasis of pregnancy
 
Recurrent pregnancy loss panel discussion
Recurrent pregnancy loss  panel discussionRecurrent pregnancy loss  panel discussion
Recurrent pregnancy loss panel discussion
 
Preterm Labor by Yinka Oyelese
Preterm Labor by Yinka OyelesePreterm Labor by Yinka Oyelese
Preterm Labor by Yinka Oyelese
 
Intra uterine growth retardation
Intra uterine growth retardationIntra uterine growth retardation
Intra uterine growth retardation
 

Ähnlich wie Hypertensive disorders of pregnancy.ppt

htninpregnancy-130120114747-phpapp01.pdf
htninpregnancy-130120114747-phpapp01.pdfhtninpregnancy-130120114747-phpapp01.pdf
htninpregnancy-130120114747-phpapp01.pdf
SavitaHanamsagar
 
2.maternity Abnormal pregnancy.pptx
2.maternity Abnormal pregnancy.pptx2.maternity Abnormal pregnancy.pptx
2.maternity Abnormal pregnancy.pptx
HgjUy7
 
Peripartum convulsions
Peripartum convulsionsPeripartum convulsions
Peripartum convulsions
rajeev sood
 
CME Hypertension in Pregnancy yoges edited.pptx
CME Hypertension in Pregnancy yoges edited.pptxCME Hypertension in Pregnancy yoges edited.pptx
CME Hypertension in Pregnancy yoges edited.pptx
yogeswary7
 
Presentation PRENANCY INDUCED HYPERTENSION
Presentation PRENANCY INDUCED HYPERTENSIONPresentation PRENANCY INDUCED HYPERTENSION
Presentation PRENANCY INDUCED HYPERTENSION
home
 
pregnancyrelatedhypertensivedisorders-150322002737-conversion-gate01_2.pdf
pregnancyrelatedhypertensivedisorders-150322002737-conversion-gate01_2.pdfpregnancyrelatedhypertensivedisorders-150322002737-conversion-gate01_2.pdf
pregnancyrelatedhypertensivedisorders-150322002737-conversion-gate01_2.pdf
GichanaElvis
 

Ähnlich wie Hypertensive disorders of pregnancy.ppt (20)

CIP.pptx
CIP.pptxCIP.pptx
CIP.pptx
 
Medical disorders in pregnancy
Medical disorders in pregnancyMedical disorders in pregnancy
Medical disorders in pregnancy
 
hellp-syndrome-–-therapeutic-challenge.ppt
hellp-syndrome-–-therapeutic-challenge.ppthellp-syndrome-–-therapeutic-challenge.ppt
hellp-syndrome-–-therapeutic-challenge.ppt
 
pre_and_eclampsia.ppt
pre_and_eclampsia.pptpre_and_eclampsia.ppt
pre_and_eclampsia.ppt
 
Htninpregnancy 130120114747-phpapp01
Htninpregnancy 130120114747-phpapp01Htninpregnancy 130120114747-phpapp01
Htninpregnancy 130120114747-phpapp01
 
htninpregnancy-130120114747-phpapp01.pdf
htninpregnancy-130120114747-phpapp01.pdfhtninpregnancy-130120114747-phpapp01.pdf
htninpregnancy-130120114747-phpapp01.pdf
 
coma and convulsions in pregnancy.ppt
coma and convulsions in pregnancy.pptcoma and convulsions in pregnancy.ppt
coma and convulsions in pregnancy.ppt
 
2.maternity Abnormal pregnancy.pptx
2.maternity Abnormal pregnancy.pptx2.maternity Abnormal pregnancy.pptx
2.maternity Abnormal pregnancy.pptx
 
Hypertensive in pregnancy new.pptx
Hypertensive in pregnancy new.pptxHypertensive in pregnancy new.pptx
Hypertensive in pregnancy new.pptx
 
Peripartum convulsions
Peripartum convulsionsPeripartum convulsions
Peripartum convulsions
 
Pih, by dr omer ajmal
Pih, by dr omer ajmalPih, by dr omer ajmal
Pih, by dr omer ajmal
 
CME Hypertension in Pregnancy yoges edited.pptx
CME Hypertension in Pregnancy yoges edited.pptxCME Hypertension in Pregnancy yoges edited.pptx
CME Hypertension in Pregnancy yoges edited.pptx
 
PRE ECLAMPSIA .pptx
PRE ECLAMPSIA .pptxPRE ECLAMPSIA .pptx
PRE ECLAMPSIA .pptx
 
Pih ppt
Pih pptPih ppt
Pih ppt
 
Pregnancy Induced Hypertension
Pregnancy Induced HypertensionPregnancy Induced Hypertension
Pregnancy Induced Hypertension
 
Hypertension in pregnancy By Dr ahmad
Hypertension in pregnancy By Dr ahmadHypertension in pregnancy By Dr ahmad
Hypertension in pregnancy By Dr ahmad
 
Presentation PRENANCY INDUCED HYPERTENSION
Presentation PRENANCY INDUCED HYPERTENSIONPresentation PRENANCY INDUCED HYPERTENSION
Presentation PRENANCY INDUCED HYPERTENSION
 
Pregnancy related hypertensive disorders
Pregnancy related hypertensive disordersPregnancy related hypertensive disorders
Pregnancy related hypertensive disorders
 
pregnancyrelatedhypertensivedisorders-150322002737-conversion-gate01_2.pdf
pregnancyrelatedhypertensivedisorders-150322002737-conversion-gate01_2.pdfpregnancyrelatedhypertensivedisorders-150322002737-conversion-gate01_2.pdf
pregnancyrelatedhypertensivedisorders-150322002737-conversion-gate01_2.pdf
 
Hypertensive Dirders of Pregnancy By Dr Zahid Ullah
Hypertensive Dirders of Pregnancy By Dr Zahid UllahHypertensive Dirders of Pregnancy By Dr Zahid Ullah
Hypertensive Dirders of Pregnancy By Dr Zahid Ullah
 

Kürzlich hochgeladen

Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
KarakKing
 
Vishram Singh - Textbook of Anatomy Upper Limb and Thorax.. Volume 1 (1).pdf
Vishram Singh - Textbook of Anatomy  Upper Limb and Thorax.. Volume 1 (1).pdfVishram Singh - Textbook of Anatomy  Upper Limb and Thorax.. Volume 1 (1).pdf
Vishram Singh - Textbook of Anatomy Upper Limb and Thorax.. Volume 1 (1).pdf
ssuserdda66b
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
QucHHunhnh
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
heathfieldcps1
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
ciinovamais
 

Kürzlich hochgeladen (20)

Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibit
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdf
 
Vishram Singh - Textbook of Anatomy Upper Limb and Thorax.. Volume 1 (1).pdf
Vishram Singh - Textbook of Anatomy  Upper Limb and Thorax.. Volume 1 (1).pdfVishram Singh - Textbook of Anatomy  Upper Limb and Thorax.. Volume 1 (1).pdf
Vishram Singh - Textbook of Anatomy Upper Limb and Thorax.. Volume 1 (1).pdf
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - English
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 

Hypertensive disorders of pregnancy.ppt

  • 2. 2 Introduction 1. Hypertensive disorders of pregnancy are one of the leading causes of maternal mortality. 2. Worldwide: 50,000 women die each year. 3. Jordan: 4th. Cause of maternal death after (hemorrhage, thrombo-embolism, and sepsis. (Jordan MMR 19.1 per 100000 live birth, 2007-2008)
  • 3. 3 Diagnosis of hypertension in pregnancy  A systolic BP of > 140 mmHg, a diastolic BP of > 90 mmHg, or both.  Hypertension is considered severe when BP > 160 for systolic or > 110 for diastolic.  It required at lest two determinations with at least 6 hours apart of bed rest.
  • 4. 4 How to measure BP in pregnant woman  Women should be allowed to sit quietly for 10-20 minutes before each blood pressure measurement.  Blood pressure should be measured in the sitting position, with the cuff at the level of the heart.  Korotkoff sounds I (the first sound) and V (the disappearance of sound) should be used to denote the systolic blood pressure (SBP) and DBP, respectively.  In about 5% of women, an exaggerated gap exists between the fourth (muffling) and fifth (disappearance) Korotkoff sounds, with the fifth sound approaching zero. In this setting, both the fourth and fifth sounds should be recorded (eg, 120/80/40, with sound I = 120, sound IV = 80, and sound V = 40), because the fourth sound will more closely approximate the true DBP.
  • 5. 5 Diagnosis of Protienurea in pregnancy  Proteinuria:  ≥ 300mg/24 hours urine.  ≥ +1 dipstick. (only applicable if the others are not avialables)  Urinary Protein:creatinine ratio:  At least 0.3 (each measured as mg/dl)
  • 6. 6 Classifications  Gestational hypertension.  Preeclampsia-Eclampsia.  Chronic hypertension with pregnancy.  Chronic hypertension with Superimposed preeclampsia.
  • 7. 7 Definitions  Gestational hypertension: – Hypertension for first time after 20 w, without Proteinuria. BP returns to normal before 12 weeks postpartum.  Chronic hypertension with pregnancy: – Hypertension antedates pregnancy and detected before 20 w, & lasts more than 12 weeks postpartum.
  • 8. 8 Definitions – Preeclampsia:  The development of hypertension and Proteinuria after 20 weeks.  May occur earlier in vesicular mole or multiple pregnancy.  Preeclampsia is diagnosed also in the presence of sever features even in the absence of protienurea (see next slide). – Eclampsia:  The occurrence of tonic-clonic convulsions (without any neurological disease) in a woman with pre- eclampsia.
  • 9. 9 Definitions  Superimposed pre-eclampsia: ¤ It is the new development of Proteinuria after 20 weeks gestation in a patient with chronic hypertension
  • 10. 10
  • 11. 11 Incidence of hypertensive disorders in pregnancy  Gestational hypertension occurs in around 5-6% of all pregnancies. More common in primigravida. Most cases are diagnosed after 34 weeks.  PE complicates 1-2% of all pregnancies. 4-7% of first pregnancies (1 in 4 of PIH) and 1% of subsequent pregnancies, rising to 16% with history of preeclampsia in first pregnancy.  Around 5-10% of PE cases are severe.  Approximately 1% of pregnancies are complicated by chronic hypertension and 20-25% of women with chronic hypertension develop preeclampsia during pregnancy.
  • 12. 12 Pre-eclampsia (PE): Definition: A diastolic BP > 90 mmHg, on at least two occasions after 20 weeks of gestation accompanied by significant proteinuria (> 300 mg/24h) and/or other systemic severe manifestations mentioned before.
  • 13. 13 Aetiology of PE: PE is the disease of theories: 1. Damage to the vascular endothelial cells. 2. Abnormal lipid metabolism. 3. Reduced anti-oxidant status. 4. Altered catecholamine homeostasis. 5. Abnormal dietary calcium, magnesium, or selenium. 6. Reduced production of nitric oxide. 7. Abnormal immune response to pregnancy.
  • 14. 14 Patho-physiology of PE:  Abnormal placentation is central to the pathogenesis of PE.  In PE there is reduction in the synthesis of nitric oxide and prostacyclin and increased production of endothelin and sensitivity to angiotensin. This result in to vasospasm and endothelial dysfunction, with subsequent platelet activation and micro thrombus formation. These are responsible for features of PE.
  • 15. 15 Multi-system Features Of Preeclampsia Multi-organ disease Kidney Systemic blood vessels Liver Fetus Cerebral blood vessels HELLP syndrome IUGR Eclampsia Proteinuria Hypertension
  • 16. 16 Clinical features of PE: Maternal syndrome: 1. PIH. 2. Proteinuria. 3. Generalized oedema. 4. Hyperuricaemia. 5. Increased haematocrit. 6. Thrombocytopenia & DIC. 7. Reduced antithrombin III. 8. Abnormal liver function tests. 9. Hypocalciuria. 10. Seizures, cortical blindness, retinal detachment (eclampsia). Fetal syndrome: 1. IUGR. 2. Fetal hypoxaemia.
  • 17. 17 Prevention of PE:  Aspirin: Low dose (81mg/day) increases the prostacycline to thromboxan ratio and prevent platelets aggregation. It should be used from 12 weeks of pregnancy in women at risk.  Calcium supplementation ( may reduce severity in women with low intake of calcium.  Antioxidant: vit.C or vit.E (not effective)  Restriction of dietary salt (not effective)
  • 18. 18 High risk women that need aspirin  Maternal disorders: – Chronic hypertension – Renal diseases – Diabetes – Autoimmune conditions  First pregnancy  Multiple pregnancy  Maternal BMI > 25  H/O preeclampsia  Age > 40 years
  • 19. 19 Investigations for PE:  Urinalysis.  24 h urine collection for total protein.  Renal function (urea,uric acid,s. creatinine).  Full blood count (platelets and haematocrit).  Liver function tests.  Coagulation profile if delivery is indicated.  Fetal biophysical profile and Doppler study.
  • 20. 20 Management of PE:  Diagnosis of PE requires admission for bed rest and close monitoring for mother and fetus.  If the diastolic BP is 90-95mmHg with only 1+ protein in the urine, out-patient management could be followed.  The definitive treatment for PE is delivery. But this depend on gestational age and feto- maternal well-being.
  • 21. 21 Management of PE (cont.): Antihypertensive therapy:  Treating the hypertension is mainly to reduce the maternal complications. It will not improve fetal condition. Acute treatment of severe hypertension:  Hydralazine: 5mg IV repeated every 20-30 min.  Nifedipine: 10mg orally repeated at 30 min. IV infusion can be used in severe cases.  Labetalol:10-20mg IV .  The dose can be doubled every 10 minutes if proper response is not achieved.  Magnesium Sulphate should be given in the management of all cases of severe preeclampsia to prevent eclampsia.
  • 22. 22 Indications for delivery in PE:  Term pregnancy.  Severe uncontrolled hypertension (>160/110).  Haemolysis with thrombocytopenia.  Progressive symptoms (headache, visual disturbances, epigastric pain).  Pulmonary oedema.  Renal failure with oliguria.  Eclampsia.  Fetal compromise ( abnormal biophysical profile).
  • 23. 23 Management of labour and delivery:  The mode of delivery is determined by Bishop’s score and feto-maternal well-being.  Induction of labour is commonly used, but CS is needed in large number of cases.  Fluids input and output should be monitored.  Prolonged pushing by the mother should be avoided.  Ergometrine should be avoided.  Pain relief is optimal (epidural analgesia if no signs of DIC).
  • 24. 24 Complications of severe PE: Eclampsia: Occurrence of convulsions in association with PE.  Incidence: 5 in 10 000 deliveries and 1-2% of severe PE cases.  High maternal and fetal mortality.  It can occur ante-natally, intra-partum and post-partum.  The patho-physiology is cerebral vasospasm leading to ischemia and cerebral edema.
  • 25. 25 Eclampsia: Diagnosis:  Women manifest excitability or hyperflexia prior to onset of seizure.  Tonic-clonic convulsions with small period of coma.  Prolonged coma mains CVA.
  • 26. 26 Management of eclampsia:  During seizure: Maintain airway, Administer oxygen and avoid supine hypotension.  Anticonvulsant therapy: 1. Magnesium sulphate 4-6 g IV followed by a maintenance infusion of 1-2 g / h. 2. Diazepam 20mg IV followed by a maintenance infusion as required. 3. Phynenton  Anticonvulsant should be continued for at least 24 h after the last convulsion.  CS is indicated unless the mother is in active labour.
  • 27. 27 Magnesium Sulfate (MgSO4):  It can be given IV or IM or SC – The therapeutic level is 4-7mEq/L. – The total dose of MgSO4 should not exceed 24 gms in 24 hours .  The dose of MgSO4 is monitored by:  Preserved patellar reflex. (7-10 mEq/L)  Respiratory rate >16/min. (10-13 mEq/L)  Urine output >100ml/4hours. (15-25 mEq/L)  Serum Mg++ level.  Is stopped 24 hours after delivery.  Antidote is ca gluconate
  • 28. 28 Complications of severe PE: HELLP syndrome: Occurs in the absence of hypertension. H: haemolysis. EL: elevated liver enzymes. LP: low platelet count.  Present with epigastric pain, tender liver, nausea & vomiting.  Headache and arterial hypertension.  Carries high maternal (acute renal failure & pulmonary odema) and fetal mortality.  Treatment similar to eclampia & DIC. Platelet transfusion and cortico-steroids are necessary.  Delivery is the treatment of choice.
  • 29. 29 Chronic hypertension in pregnancy Causes of CHT: 1. Essential hypertension. 2. Renal diseases (glomerulonephritis, polycystic disease, diabetic nephropathy, renal artery stenosis). 3. Collagen vascular diseases ( systemic lupus erythematosus, scleroderma). 4. Coarctation of the aorta. 5. Phaeochromocytoma.
  • 30. 30 Chronic hypertension in pregnancy  The main concern that one third of these women will develop superimposed PIH. Risk factors for preeclampsia in CHT: 1. Renal disease. 2. Maternal age > 40 years. 3. Diabetes. 4. SLE. 5. Coarctation of the aorta. 6. BP > 160/100 mmHg in early pregnancy.
  • 31. 31 Chronic hypertension in pregnancy Feto-Maternal risks: 1. Eclampsia. 2. Abruptio-placenta. 3. Heart failure. 4. Intracerebral haemorrhage. 5. IUGR.
  • 32. 32 Long-term treatment of hypertension This is used mainly in CHD.  Methyldopa is the most common in use (least side effects). 1-2 g / day in three divided doses.  Nifedipine 40 mg / day in two divided doses.  Labetolol and Hydralazine can also be used.  ACE inhibitors, Angiotensin II blocker, and Chlorothiazide should be avoided because of teratogenic effect.
  • 33. 33 Chronic hypertension in pregnancy Management:  Investigations should be performed to diagnose the cause of hypertension.  If the woman is on antihypertensive drugs, she should continue on it, except for angiotensin converting enzyme inhibitors (captoprel) because of risk of fetal damage. Care should be taken not to excessively lower the BP as this may affect the fetal healthy.  Maternal and fetal well-being should be monitored through the pregnancy.
  • 34. 34 Chronic hypertension in pregnancy Management (cont.):  In severe cases admission is needed.  The obstetric management is similar to that of preeclampsia.  Timing the delivery must be individualized according to the feto-maternal well-being.  Induction of labour or CS should be selected according to the case.
  • 35. 35